Saddle Brook Office
Park 80 West – Plaza I
250 Pehle Avenue
Suite 601
Saddle Brook, NJ 07663

East Brunswick Office
2 Tower Center Blvd.
Suite 1401A
East Brunswick, NJ 08816

Phone: +1 (201) 961-9000

ACETO Subsidiary, Rising Pharmaceuticals, Launches Atenolol Tablets, 25mg, 50mg and 100mg

by Rising Pharmaceuticals | Feb 08, 2018

PORT WASHINGTON, N.Y., Feb. 07, 2018 (GLOBE NEWSWIRE) -- ACETO Corporation (NASDAQ:ACET), an international company engaged in the development, marketing, sale and distribution of Human Health products, Pharmaceutical Ingredients and Performance Chemicals, today announced that Rising Pharmaceuticals, its finished dosage form generics subsidiary, has launched Atenolol Tablets, 25mg, 50mg and 100mg, an FDA-approved generic version of the reference listed drug, TENORMIN®  from Alvogen Malta Operations LTD, which is indicated for hypertension.  Atenolol is currently listed on the FDA Drug Shortages database. The Atenolol Tablets, 25mg, 50mg and 100mg, had sales of approximately $60.9 million for the 12 months ending December 2017, according to IMS Health.

ACETO Corporation sells generic prescription products and over-the-counter pharmaceutical products under its Rising label to leading wholesalers, chain drug stores, distributors and mass merchandisers, and the launch of the Atenolol Tablets, 25mg, 50mg and 100mg, adds to its significant human pharmaceutical franchise.  Rising Pharmaceuticals has built a commercial portfolio of over 140 products currently in the U.S. market. It also has a development portfolio of more than 50 ANDAs filed with the FDA or pending launch, representing over $12.5 billion in addressable market value, using recent IMS sales data.  


ACETO Corporation, incorporated in 1947 and with offices and operations in 10 countries, is engaged in the development, marketing, sale and distribution of Human Health products (finished dosage form generics and nutraceuticals), Pharmaceutical Ingredients (pharmaceutical intermediates and active pharmaceutical ingredients) and Performance Chemicals (specialty chemicals and agricultural protection products).


This news release contains forward-looking statements as that term is defined in the federal securities laws.  The events described in forward-looking statements contained in this news release may not occur.  Generally, these statements relate to our business plans or strategies, projected or anticipated benefits or other consequences of ACETO’s plans or strategies, financing plans, projected or anticipated benefits from acquisitions that ACETO may make, or a projection involving anticipated revenues, earnings or other aspects of ACETO’s operating results or financial position, and the outcome of any contingencies.  Any such forward-looking statements are based on current expectations, estimates and projections of management. ACETO intends for these forward-looking statements to be covered by the safe-harbor provisions for forward-looking statements. Words such as "may," "will," "expect," "believe," "anticipate," "project," "plan," "intend," "estimate," and "continue," and their opposites and similar expressions are intended to identify forward-looking statements.  The forward-looking statements contained in this press release include, but are not limited to, statements regarding the Company’s strategic initiatives including selling finished dosage form generic drugs, and statements regarding the prospects for long-term growth.  ACETO cautions you that these statements are not guarantees of future performance or events and are subject to a number of uncertainties, risks and other influences, many of which are beyond ACETO’s control, which may influence the accuracy of the statements and the projections upon which the statements are based.  Factors that could cause actual results to differ materially from those set forth or implied by any forward-looking statement include, but are not limited to, risks and uncertainties discussed in ACETO’s reports filed with the Securities and Exchange Commission, including, but not limited to, ACETO’s Annual Report on Form 10-K for the fiscal year ended June 30, 2017 and other filings, including Amendment No. 1 on Form 10-K/A to our annual report on Form 10-K for the fiscal year ended June 30, 2017. Copies of these filings are available at www.sec.gov

Any one or more of these uncertainties, risks and other influences could materially affect ACETO’s results of operations and whether forward-looking statements made by ACETO ultimately prove to be accurate. In addition, periodic high-margin product sales may have a positive material financial impact in a given quarter that may be non-recurring in future quarters, thereby rendering one quarter's performance not useful as a predictor of future quarters' results.  ACETO’s actual results, performance and achievements could differ materially from those expressed or implied in these forward-looking statements.  ACETO undertakes no obligation to publicly update or revise any forward-looking statements, whether from new information, future events or otherwise.

Investor Relations Contact:
Jody Burfening
(212) 838-377